A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment

Transfusion

Volumn 48, Issue 6, 2008, Pages 1061-1071

  Osselaer, Jean C ^b   Messe, Nathalie ^b   Hervig, Tor ^b   Bueno, Jose ^b   Castro, Emma ^b   Espinosa, Aurora ^b   Accorsi, Patrizia ^b   Junge, Klaus ^b   Jacquet, Michele ^b   Flament, Jocelyne ^b   Corash, Laurence ^a  

^a CERUS CORPORATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN;

ACUTE LUNG INJURY; ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; BLOOD COMPONENT; CHILD; CHILL; COHORT ANALYSIS; DYSPNEA; FEMALE; FEVER; FLUSHING; HUMAN; HYPOTENSION; INFANT; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; PHOTOCHEMISTRY; PROSPECTIVE STUDY; PRURITUS; RASH; RISK ASSESSMENT; THROMBOCYTE TRANSFUSION; ULTRAVIOLET RADIATION; URTICARIA; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PHOTOCHEMISTRY; PLATELET TRANSFUSION; RISK FACTORS; SAFETY; SEPSIS;

EID: 44849088730     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01643.x     Document Type: Article

References (20)

1. van Rhenen DJ, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003 101 : 2426 33.
2. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004 104 : 1534 41.
3. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin J-S, Corash L, Conlan MG for the SPRINT Study Group. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005 45 : 1864 75.
4. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer C, Woodson R. Factors affecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005 105 : 4106 14.
5. Andreu G, Morel P, Forestier F, Rebibo D, Janvier G, Herve P. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 2002 42 : 1356 64.
6. Faber JC. Haemovigilance in Europe: now and tomorrow. In : Rouger P, Hossenlopp C, editors. Blood transfusion in Europe. Paris : Elsevier SAS 2005. p. 2 13 32.
7. Ware L, Matthay M. The acute respiratory distress syndrome. N Engl J Med 2000 342 : 1334 49.
8. Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, Lioure B, Hastka J, Marblie S, Mayaudon V, Lin L, Lin JS, Conlan MG, Flament J. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005 45 : 1443 52.
9. Grass JA, Wafa T, Reames A, Wages D, Corash L, Ferrara. JL, Lin L. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999 93 : 3140 7.
10. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F. Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference. Vox Sang 2007 93 : 179 82.
11. Chambers LA, Kruskall MS, Pacini DG, Donovan LM. Febrile reactions after platelet transfusion: the effect of single versus multiple donors. Transfusion 1990 30 : 219 21.
12. deWildt-Eggen J, Nauta S, Schrijver JG, Kooy Mv M, Bins M, van Prooijen HC. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000 40 : 398 403.
13. Heddle NM, Blajchman MA, Meyer RM, Lipton JH, Walker IR, Sher GD, Constantini LA, Patterson B, Roberts RS, Thorpe KE, Levine MN. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and pre-storage WBC-reduced platelets. Transfusion 2002 42 : 556 66.
14. Kerkhoffs JH, Eikenboom JC, Schipperus MS, van Wordragen-Vlaswinkel RJ, Brand R, Harvey MS, de Vries RR, Barge R, van Rhenen DJ, Brand A. A muticenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006 108 : 3210 5.
15. Osselaer JC, Doyen C, Messe N, Van Hooydonk M, Jacquet M, Sonnet A, Bosly A, Flament J, Corash L. Routine use of platelet components prepared with photochemical treatment (INTERCEPT platelets): impact on clinical outcomes and resources. Blood 2005 106 : 129a.
16. Heddle NM, Kalma L, Singer J, Richards C, Fedak P, Walker I, Kelton JG. The role of plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994 331 : 625 8.
17. Mangano MM, Chambers LA, Kruskall MS. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions. Am J Clin Pathol 1991 95 : 733 8.
18. Heddle NM, Klama LN, Griffith L, Roberts R, Shukla G, Kelton JG. A prospective study to identify risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993 33 : 794 7.
19. Enright H. Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multi-center clinical trial. Transfusion 2003 43 : 1545 52.
20. Angelini-Tibert MF, Currie C, Slaedts M, Corash LM, Rasongles P. Safety of platelet components prepared with photochemical treatment (INTERCEPT) transfused to pediatric oncology-hematology patients. Transfusion 2007 43 (S3 22A.